Suraksha Diagnostic Limited — Investor Meet, 17-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Suraksha Diagnostic reported a strong Q1 FY27. Revenue jumped 21% to INR 88.7 Cr, with EBITDA up 28% to INR 31.5 Cr (36% margin) and PAT soaring 40% to INR 12.8 Cr (14.7% margin). Management noted healthy business momentum and expansion.

Key drivers include new centers turning profitable and mature centers sustaining 40.9% EBITDA. Genomics revenue grew 136% to INR 1.37 Cr, with new offerings like Alzheimer's tests. The company is aggressively expanding across East/Northeast India, targeting 100 centers by FY28, with a positive outlook on continued margin expansion and growth.